Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Surgery Partners (SGRY) EBITDA Margin (2016 - 2025)

Surgery Partners (SGRY) has disclosed EBITDA Margin for 12 consecutive years, with 12.45% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 225.0% to 12.45% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11.77% through Dec 2025, up 57.0% year-over-year, with the annual reading at 16.92% for FY2025, 107.0% up from the prior year.
  • EBITDA Margin hit 12.45% in Q4 2025 for Surgery Partners, down from 12.87% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 18.81% in Q4 2021 to a low of 6.96% in Q1 2023.
  • Historically, EBITDA Margin has averaged 12.35% across 5 years, with a median of 12.44% in 2022.
  • Biggest five-year swings in EBITDA Margin: soared 764bps in 2021 and later plummeted -988bps in 2023.
  • Year by year, EBITDA Margin stood at 18.81% in 2021, then fell by -29bps to 13.32% in 2022, then increased by 4bps to 13.79% in 2023, then grew by 7bps to 14.7% in 2024, then decreased by -15bps to 12.45% in 2025.
  • Business Quant data shows EBITDA Margin for SGRY at 12.45% in Q4 2025, 12.87% in Q3 2025, and 13.52% in Q2 2025.